{"id":29837,"date":"2026-04-19T14:44:00","date_gmt":"2026-04-19T21:44:00","guid":{"rendered":"https:\/\/getheally.com\/patients\/news\/how-to-switch-from-compounded-semaglutide-to-compounded-tirzepatide-copy"},"modified":"2026-04-21T07:09:24","modified_gmt":"2026-04-21T14:09:24","slug":"tirzepatide-vs-semaglutide-dosage-for-weight-loss","status":"publish","type":"post","link":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","title":{"rendered":"Tirzepatide vs semaglutide: key differences, efficacy &amp; which is right for you (2026)"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Two medications now dominate the GLP-1 weight loss and diabetes landscape: <\/span><a href=\"https:\/\/getheally.com\/patients\/semaglutide\"><span style=\"font-weight: 400;\">semaglutide<\/span><\/a><span style=\"font-weight: 400;\"> (sold as <\/span><a href=\"https:\/\/getheally.com\/patients\/ozempic\"><span style=\"font-weight: 400;\">Ozempic<\/span><\/a><span style=\"font-weight: 400;\">, <\/span><a href=\"https:\/\/getheally.com\/patients\/wegovy\"><span style=\"font-weight: 400;\">Wegovy<\/span><\/a><span style=\"font-weight: 400;\">, and <\/span><a href=\"https:\/\/getheally.com\/patients\/rybelsus\"><span style=\"font-weight: 400;\">Rybelsus<\/span><\/a><span style=\"font-weight: 400;\">) and <\/span><a href=\"https:\/\/getheally.com\/patients\/tirzepatide\"><span style=\"font-weight: 400;\">tirzepatide<\/span><\/a><span style=\"font-weight: 400;\"> (sold as <\/span><a href=\"https:\/\/getheally.com\/patients\/mounjaro\"><span style=\"font-weight: 400;\">Mounjaro<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/getheally.com\/patients\/zepbound\"><span style=\"font-weight: 400;\">Zepbound<\/span><\/a><span style=\"font-weight: 400;\">). They are often discussed together, prescribed for similar conditions, and confused for one another \u2014 yet they are meaningfully different drugs with distinct mechanisms, efficacy profiles, approval statuses, and ideal candidates.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This guide breaks down every major difference between tirzepatide and semaglutide in 2026, drawing on the latest clinical trial data, real-world studies, and updated FDA guidance \u2014 so you and your provider can make a genuinely informed decision.<\/span><\/p>\n<h2 id=\"key-takeaways\"><b>Key takeaways<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Both tirzepatide and semaglutide are once-weekly injectable GLP-1 medications that produce significant weight loss and improve blood sugar control.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tirzepatide is a dual GLP-1 + GIP receptor agonist; semaglutide is a GLP-1 agonist only \u2014 this is the core mechanistic difference.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In the definitive SURMOUNT-5 head-to-head trial (NEJM 2025), tirzepatide produced ~20% weight loss vs. ~14% with semaglutide over 72 weeks.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Side effect profiles are broadly similar; both carry the same FDA boxed warning for thyroid tumors.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Semaglutide has a longer safety track record, proven cardiovascular benefit data (SELECT trial), and FDA approval for adolescents aged 12+.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The right choice depends on your goals, health history, insurance, and individual response \u2014 not just efficacy averages.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Consult a <\/span><a href=\"https:\/\/getheally.com\/patients\/weight-loss-prescription\"><span style=\"font-weight: 400;\">Heally licensed provider<\/span><\/a><span style=\"font-weight: 400;\"> to determine which medication is right for you.<\/span><\/li>\n<\/ul>\n<h2 id=\"the-core-difference-between-semaglutide-and-tirzepatide-how-each-drug-works\"><b>The core difference between semaglutide and tirzepatide: how each drug works<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The most important difference between tirzepatide and semaglutide is their mechanism of action \u2014 specifically, which hormone receptors they activate.<\/span><\/p>\n<h3 id=\"semaglutide\"><span style=\"font-weight: 400;\">Semaglutide\u00a0<\/span><\/h3>\n<p><b>Semaglutide<\/b><span style=\"font-weight: 400;\"> is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a gut hormone released after eating that signals the brain to reduce appetite, slows gastric emptying (so you feel fuller longer), stimulates insulin release from the pancreas, and suppresses glucagon (which would otherwise raise blood sugar). Semaglutide mimics this hormone with a longer half-life, making once-weekly dosing possible.<\/span><\/p>\n<h3 id=\"tirzepatide\"><span style=\"font-weight: 400;\">Tirzepatide<\/span><\/h3>\n<p><b>Tirzepatide<\/b><span style=\"font-weight: 400;\"> is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist \u2014 sometimes called a &#8220;twincretin.&#8221; GIP is a second gut hormone involved in insulin secretion, fat storage regulation, and energy metabolism. By activating GIP receptors alongside GLP-1 receptors simultaneously, tirzepatide creates synergistic metabolic effects that exceed what either hormone achieves alone. Critically, GIP receptor activation in adipose (fat) tissue appears to enhance fat mobilization and energy expenditure beyond what GLP-1 can do alone \u2014 which helps explain tirzepatide&#8217;s superior weight loss outcomes in clinical trials.<\/span><\/p>\n<p><b><i>Mechanism edge: tirzepatide<\/i><\/b><\/p>\n<p><i><span style=\"font-weight: 400;\">Tirzepatide&#8217;s dual GLP-1 + GIP action creates broader metabolic benefits. However, both mechanisms are clinically proven \u2014 semaglutide&#8217;s GLP-1-only approach produces substantial, well-documented weight loss and glycemic control in its own right.<\/span><\/i><\/p>\n<h2 id=\"fda-approvals-what-each-drug-is-officially-indicated-for\"><b>FDA approvals: what each drug is officially indicated for<\/b><\/h2>\n<table>\n<tbody>\n<tr>\n<td><b>Indication<\/b><\/td>\n<td><b>Semaglutide<\/b><\/td>\n<td><b>Tirzepatide<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Type 2 diabetes management<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Ozempic (injectable), Rybelsus (oral)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Mounjaro<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Chronic weight management (obesity)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy (adults + adolescents 12+)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Zepbound (adults only)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Cardiovascular risk reduction (ASCVD)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy (SELECT trial, 2023)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Studies ongoing (SURPASS-CVOT)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Obstructive sleep apnea (OSA)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Not approved<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Zepbound (approved 2024)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Use in adolescents (12\u201317 years)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy (12+ years, obesity)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Not approved under 18<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Oral formulation available<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Rybelsus (oral tablets, T2D)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Injectable only<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Metabolic dysfunction-associated steatohepatitis (MASH)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy HD (approved 2025)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Not yet approved<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i><span style=\"font-weight: 400;\">Sources: FDA prescribing information for Wegovy (2025), Mounjaro (2026), Zepbound (2025); <\/span><\/i><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s023lbl.pdf\"><i><span style=\"font-weight: 400;\">FDA Wegovy label 2025<\/span><\/i><\/a><i><span style=\"font-weight: 400;\">; <\/span><\/i><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215866s009lbl.pdf\"><i><span style=\"font-weight: 400;\">FDA Mounjaro label 2026<\/span><\/i><\/a><\/p>\n<p><b><i>Approvals breadth edge: semaglutide<\/i><\/b><\/p>\n<p><i><span style=\"font-weight: 400;\">Semaglutide currently holds more FDA indications \u2014 including proven cardiovascular benefit, adolescent use, an oral formulation, and the newly approved MASH indication \u2014 giving it an advantage in breadth of clinical application.<\/span><\/i><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-efficacy-in-weight-loss-comparison\"><b>Semaglutide and tirzepatide efficacy in weight loss comparison<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">This is where the two drugs diverge most clearly, and where the most robust clinical evidence now exists.<\/span><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Drug<\/b><\/td>\n<td><b>Trial<\/b><\/td>\n<td><b>Duration<\/b><\/td>\n<td><b>Dosage<\/b><\/td>\n<td><b>Mean Weight Reduction<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Tirzepatide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">SURMOUNT-5<\/span><\/td>\n<td><span style=\"font-weight: 400;\">72 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u2014<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u221220.2%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Semaglutide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">SURMOUNT-5<\/span><\/td>\n<td><span style=\"font-weight: 400;\">72 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u2014<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u221213.7%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Tirzepatide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">SURMOUNT-1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">72 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">15 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u221222.5%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Semaglutide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">STEP-1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">68 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.4 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u221214.9%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">The SURMOUNT-5 trial \u2014 published in the <\/span><i><span style=\"font-weight: 400;\">New England Journal of Medicine<\/span><\/i><span style=\"font-weight: 400;\"> in May 2025 \u2014 was the first randomized, head-to-head comparison of the two medications in patients with obesity but without type 2 diabetes. It enrolled 751 adults and ran for 72 weeks at the maximum tolerated dose of each drug. Tirzepatide produced a mean weight reduction of 20.2% compared to 13.7% with semaglutide \u2014 a statistically significant 6.5 percentage point difference. Participants on tirzepatide were also more likely to achieve weight reductions of 10%, 15%, 20%, and 25% compared to those on semaglutide.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A 2025 meta-analysis in PMC (covering 36,754 tirzepatide and 106,057 semaglutide participants across multiple studies) confirmed tirzepatide&#8217;s advantage, finding an average 4.23 percentage points greater weight loss with tirzepatide \u2014 an effect that was both dose- and duration-dependent. Real-world data from a large U.S. study of over 18,000 patients found tirzepatide users lost approximately 15.3% of body weight at 12 months compared to 8.3% with semaglutide.<\/span><\/p>\n<p><b><i>Weight loss edge: tirzepatide<\/i><\/b><\/p>\n<p><i><span style=\"font-weight: 400;\">The clinical evidence is now definitive \u2014 tirzepatide produces greater average weight loss than semaglutide across trials and real-world data. That said, semaglutide still produces clinically meaningful, life-improving weight loss for the majority of patients.<\/span><\/i><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-efficacy-in-blood-sugar-control-for-type-2-diabetes\"><b>Semaglutide and tirzepatide efficacy in blood sugar control for type 2 diabetes<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Both medications significantly reduce HbA1c (the key long-term blood sugar marker), but tirzepatide again shows superior results in head-to-head comparisons.<\/span><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Metric<\/b><\/td>\n<td><b>Tirzepatide<\/b><\/td>\n<td><b>Semaglutide<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">HbA1c reduction (max dose, trials)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u22122.0% to \u22122.4%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u22121.6% to \u22121.9%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">HbA1c reduction (real-world, 12 mo)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u22121.3% (GLP-1 na\u00efve patients)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u22120.9% (GLP-1 na\u00efve patients)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Weight lost (real-world, T2D, 12 mo)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u221210.2 kg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u22126.1 kg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">SURPASS-2 vs. 1 mg sema (HbA1c)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u22122.0 to \u22122.3% (all tirzepatide doses)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u22121.86% (1 mg weekly)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Cardiovascular outcomes (MACE)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Data pending (SURPASS-CVOT)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Proven reduction (SELECT trial)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i><span style=\"font-weight: 400;\">Sources: <\/span><\/i><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12579026\/\"><i><span style=\"font-weight: 400;\">Real-world HbA1c study, PMC 2025<\/span><\/i><\/a><i><span style=\"font-weight: 400;\">; <\/span><\/i><a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2107519\"><i><span style=\"font-weight: 400;\">SURPASS-2, NEJM 2021<\/span><\/i><\/a><\/p>\n<p><span style=\"font-weight: 400;\">An important caveat: semaglutide&#8217;s proven cardiovascular benefit is a meaningful clinical differentiator. The SELECT trial (2023) demonstrated that Wegovy significantly reduces major adverse cardiovascular events (MACE) \u2014 heart attack, stroke, cardiovascular death \u2014 in patients with established cardiovascular disease and obesity. Tirzepatide&#8217;s cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing as of 2026. For patients with a history of heart disease, this proven benefit may tip the clinical balance toward semaglutide.<\/span><\/p>\n<p><b><i>2026 Update. <\/i><\/b><i><span style=\"font-weight: 400;\">\u00a0In 2025, the FDA approved <\/span><\/i><b><i>Wegovy HD<\/i><\/b><i><span style=\"font-weight: 400;\"> \u2014 a higher-dose semaglutide formulation \u2014 for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. This expanded semaglutide&#8217;s clinical reach significantly. Additionally, Zepbound (tirzepatide) received approval for obstructive sleep apnea (OSA) in adults with obesity in 2024, marking the first FDA-approved pharmacotherapy for OSA.<\/span><\/i><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-dosing-comparison\"><b>Semaglutide and tirzepatide dosing comparison<\/b><\/h2>\n<table>\n<tbody>\n<tr>\n<td><b>Dosing Feature<\/b><\/td>\n<td><b>Semaglutide<\/b><\/td>\n<td><b>Tirzepatide<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Starting dose<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.25 mg weekly (injectable) \/ 3 mg daily (oral)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.5 mg weekly<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Titration interval<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Every 4 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Every 4 weeks<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Maintenance dose range<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.5 mg \u2013 2.4 mg weekly (injectable)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5 mg \u2013 15 mg weekly<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Maximum dose<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.4 mg weekly (Wegovy) \/ 2 mg weekly (Ozempic)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">15 mg weekly<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Administration<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Subcutaneous injection or oral tablet (Rybelsus)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Subcutaneous injection only<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Injection device<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Pre-filled auto-injector pen<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Pre-filled auto-injector pen<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Half-life<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~7 days<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~5 days<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"semaglutide-and-tirzepatide-side-effects-how-do-they-compare\"><b>Semaglutide and tirzepatide side effects: how do they compare?<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Because both drugs activate the GLP-1 pathway, their side effect profiles are substantially similar. The differences are matters of degree rather than kind.<\/span><\/p>\n<p><b>Common side effects shared by both medications:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nausea (most common, usually transient \u2014 peaks during dose escalation)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vomiting<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diarrhea or constipation<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Decreased appetite and early satiety<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Bloating or stomach discomfort<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Injection site reactions<\/span><\/li>\n<\/ul>\n<p><b>Key safety warnings that apply to both drugs:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>FDA Boxed Warning (both):<\/b><span style=\"font-weight: 400;\"> Possible risk of thyroid C-cell tumors, based on animal studies. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pancreatitis risk \u2014 both carry a warning; discontinue if suspected.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Gallbladder disease \u2014 both associated with increased gallstone and cholecystitis risk, particularly with rapid weight loss.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Hypoglycemia \u2014 especially in patients with type 2 diabetes who are also taking insulin or sulfonylureas.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Renal impairment \u2014 both can worsen dehydration-related acute kidney injury if GI side effects are severe.<\/span><\/li>\n<\/ul>\n<h3 id=\"where-do-they-differ-in-side-effects\"><span style=\"font-weight: 400;\">Where do they differ in side effects?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">A meta-analysis covering over 28,000 patients found that while the overall rate of GI adverse events was similar (approximately 52\u201353% of patients in both groups), serious adverse events occurred somewhat more frequently with higher tirzepatide doses (5.3\u20137% at 10\u201315 mg) compared to semaglutide (2.8%). Appetite suppression can also be more pronounced on tirzepatide, which some patients welcome but others find uncomfortable.<\/span><\/p>\n<p><b><i>Side effect tolerability edge: semaglutide (slight)<\/i><\/b><\/p>\n<p><span style=\"font-weight: 400;\">Both drugs have similar side effect profiles overall. Semaglutide has a slightly better serious adverse event rate in comparative data, and its GLP-1-only mechanism tends to produce somewhat less pronounced appetite suppression. Semaglutide also benefits from a longer real-world safety track record (approved for weight loss since 2021).<\/span><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-difference-in-cost-and-insurance-in-2026\"><b>Semaglutide and tirzepatide difference in cost and insurance in 2026<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Cost is often the deciding factor for many patients. Brand-name versions of both medications are expensive without insurance, but the landscape has shifted considerably in 2026.<\/span><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Cost factor<\/b><\/td>\n<td><b>Semaglutide<\/b><\/td>\n<td><b>Tirzepatide<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Brand-name monthly cost (list price)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$1,000\u2013$1,350 (Wegovy\/Ozempic)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$1,050\u2013$1,500 (Mounjaro\/Zepbound)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Insurance coverage (obesity)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Broader \u2014 Wegovy has longer formulary history<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Growing \u2014 Zepbound gaining coverage<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Manufacturer savings card<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Novo Nordisk savings program available<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Eli Lilly savings card available<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Compounded availability (2026)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Variable \u2014 FDA shortage status fluctuates<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Available through licensed pharmacies<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Cost per 1% body weight reduction<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$1,845 (brand-name)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$985 (brand-name)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i><span style=\"font-weight: 400;\">Note: Compounded GLP-1 options through licensed pharmacies can reduce costs significantly. Prices as reported in 2026; confirm current pricing with your pharmacy or provider. Source: <\/span><\/i><a href=\"https:\/\/www.drugs.com\/medical-answers\/tirzepatide-semaglutide-how-compare-3576410\/\"><i><span style=\"font-weight: 400;\">Drugs.com comparison, updated March 2026<\/span><\/i><\/a><\/p>\n<p><span style=\"font-weight: 400;\">When measured in cost per percentage point of body weight lost, tirzepatide is actually more cost-efficient than semaglutide at brand-name prices, despite its similar or slightly higher list price \u2014 because it produces greater weight loss per dollar spent.<\/span><\/p>\n<h2 id=\"who-should-choose-tirzepatide\"><b>Who should choose tirzepatide?<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patients whose primary goal is maximum weight loss and who want the drug with the strongest efficacy data<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Those who have plateaued on semaglutide and need a more potent treatment<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Adults with obesity and obstructive sleep apnea (the only FDA-approved pharmacotherapy for OSA)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Type 2 diabetes patients who need stronger HbA1c reduction beyond what semaglutide can provide<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patients for whom insurance covers tirzepatide at comparable or lower cost to semaglutide<\/span><\/li>\n<\/ul>\n<h2 id=\"who-should-choose-semaglutide\"><b>Who should choose semaglutide?<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patients with established cardiovascular disease (heart attack, stroke history) who benefit from semaglutide&#8217;s proven MACE reduction (SELECT trial)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Adolescents aged 12\u201317 with obesity \u2014 Wegovy is the only approved GLP-1 option in this age group<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patients who prefer or need an oral medication option (<\/span><a href=\"https:\/\/getheally.com\/patients\/rybelsus\"><span style=\"font-weight: 400;\">Rybelsus<\/span><\/a><span style=\"font-weight: 400;\"> tablets for type 2 diabetes)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Those for whom semaglutide is more affordable or better covered by insurance<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patients with metabolic dysfunction-associated steatohepatitis (MASH) \u2014 Wegovy HD received approval for this indication in 2025<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">First-time GLP-1 users who want to start with the medication with the longest real-world safety track record<\/span><\/li>\n<\/ul>\n<h2 id=\"frequently-asked-questions\"><b>Frequently Asked Questions<\/b><\/h2>\n<p><b>Is tirzepatide stronger than semaglutide?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">In terms of average weight loss and blood sugar reduction in clinical trials, yes \u2014 tirzepatide consistently outperforms semaglutide. The SURMOUNT-5 head-to-head trial confirmed tirzepatide produced about 20% weight loss vs. about 14% with semaglutide over 72 weeks. However, &#8220;stronger&#8221; doesn&#8217;t mean &#8220;right for everyone.&#8221; Individual responses vary significantly, and semaglutide produces clinically meaningful results for the majority of patients who take it.<\/span><\/p>\n<p><b>Can I take tirzepatide and semaglutide together?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">No. These medications should never be taken simultaneously. Both act on GLP-1 receptors, and combining them greatly increases the risk of severe GI side effects, hypoglycemia (in diabetes patients), and other adverse events, without providing additional clinical benefit. Always complete one medication cycle before starting the other, with your provider&#8217;s guidance.<\/span><\/p>\n<p><b>Which is better for weight loss: Ozempic or Mounjaro?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Mounjaro (tirzepatide) produces greater average weight loss than Ozempic (semaglutide) in clinical trials. However, note that Ozempic is technically approved for type 2 diabetes, not obesity \u2014 Wegovy is the weight-loss-approved form of semaglutide. For a direct comparison see our pages on <\/span><a href=\"https:\/\/getheally.com\/patients\/ozempic\"><span style=\"font-weight: 400;\">Ozempic<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/getheally.com\/patients\/mounjaro\"><span style=\"font-weight: 400;\">Mounjaro<\/span><\/a><span style=\"font-weight: 400;\">. For obesity treatment, the relevant comparison is Zepbound vs. Wegovy.<\/span><\/p>\n<p><b>Which drug has fewer side effects?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Both medications have broadly similar side effect profiles dominated by GI symptoms \u2014 nausea, vomiting, diarrhea, and constipation. Comparative data shows slightly higher rates of serious adverse events with high-dose tirzepatide (10\u201315 mg). If you had intolerable side effects on one medication, switching to the other under medical supervision may improve tolerability, since the molecules are different enough to produce different individual responses.<\/span><\/p>\n<p><b>Does semaglutide have better cardiovascular benefits than tirzepatide?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Currently, yes \u2014 semaglutide has proven cardiovascular benefit from the SELECT trial (2023), which demonstrated significant reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with obesity and established heart disease. Tirzepatide&#8217;s cardiovascular outcomes trial (SURPASS-CVOT) is ongoing as of 2026, so this comparison may change once those results are published.<\/span><\/p>\n<p><b>Which is more cost-effective?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Despite similar or slightly higher list prices, tirzepatide&#8217;s greater weight loss per patient makes it more cost-efficient per percentage point of body weight lost \u2014 approximately $985 vs. $1,845 per 1% weight reduction at brand-name prices. However, out-of-pocket cost depends heavily on your insurance coverage, which varies between patients and plans. Always check your specific formulary before deciding based on cost.<\/span><\/p>\n<p><b>Is there a generic version of either drug available?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">No FDA-approved generics exist for either tirzepatide or semaglutide as of April 2026. Both are still under patent protection. Compounded semaglutide and tirzepatide \u2014 prepared by licensed compounding pharmacies using pharmaceutical-grade active ingredients \u2014 have provided cost-effective alternatives for many patients, though their availability fluctuates with FDA shortage determinations. Discuss compounded options with your Heally provider.<\/span><\/p>\n<h2 id=\"resources-further-reading\"><b>Resources &amp; further reading<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2416394\"><span style=\"font-weight: 400;\">SURMOUNT-5: Tirzepatide vs. Semaglutide for Obesity (NEJM, 2025)<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2821080\"><span style=\"font-weight: 400;\">Rodriguez et al. \u2014 Semaglutide vs. Tirzepatide for Weight Loss (JAMA Internal Medicine, 2024)<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12151102\/\"><span style=\"font-weight: 400;\">Meta-analysis: Comparative Efficacy of Tirzepatide vs. Semaglutide (PMC, 2025)<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12579026\/\"><span style=\"font-weight: 400;\">Real-world HbA1c and weight outcomes: Tirzepatide vs. Semaglutide in T2D (PMC, 2025)<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2107519\"><span style=\"font-weight: 400;\">SURPASS-2: Tirzepatide vs. Semaglutide in Type 2 Diabetes (NEJM, 2021)<\/span><\/a><\/li>\n<\/ul>\n<h2 id=\"medical-disclaimer\"><span style=\"font-weight: 400;\">Medical disclaimer<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided reflects publicly available clinical data and general guidance as of April 2026. Clinical trial results represent population averages and individual responses to any medication will vary. Both semaglutide and tirzepatide are prescription medications requiring a licensed healthcare provider&#8217;s evaluation and prescription. Do not start, stop, or change any medication without consulting your doctor. Heally connects patients with independent licensed healthcare providers; Heally itself does not prescribe medications or provide medical advice. All pricing information is approximate and subject to change; verify costs with your pharmacy and insurance carrier.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"Two medications now dominate the GLP-1 weight loss and diabetes landscape: semaglutide (sold as Ozempic, Wegovy, and Rybelsus)&hellip;\n","protected":false},"author":12,"featured_media":29840,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1838,1829],"tags":[2279,1860,2278,1831,1797,1793,1830,1832],"class_list":{"0":"post-29837","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-semaglutide-weight-loss","8":"category-tirzepatide","9":"tag-dosing","10":"tag-glp-1","11":"tag-medication-comparison","12":"tag-mounjaro","13":"tag-ozempic","14":"tag-semaglutide","15":"tag-tirzepatide","16":"tag-zepbound"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally<\/title>\n<meta name=\"description\" content=\"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally\" \/>\n<meta property=\"og:description\" content=\"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you\" \/>\n<meta property=\"og:url\" content=\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\" \/>\n<meta property=\"og:site_name\" content=\"Heally\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/getheally.com\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-19T21:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T14:09:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Vanessa Niles MD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vanessa Niles MD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#article\",\"isPartOf\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\"},\"author\":{\"name\":\"Vanessa Niles MD\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/0c6491634669dd305779a764129e92d1\"},\"headline\":\"Tirzepatide vs semaglutide: key differences, efficacy &amp; which is right for you (2026)\",\"datePublished\":\"2026-04-19T21:44:00+00:00\",\"dateModified\":\"2026-04-21T14:09:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\"},\"wordCount\":2274,\"publisher\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage\"},\"thumbnailUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\",\"keywords\":[\"Dosing\",\"glp-1\",\"Medication Comparison\",\"mounjaro\",\"Ozempic\",\"semaglutide\",\"tirzepatide\",\"zepbound\"],\"articleSection\":[\"Semaglutide\",\"Tirzepatide\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\",\"url\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\",\"name\":\"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally\",\"isPartOf\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage\"},\"thumbnailUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\",\"datePublished\":\"2026-04-19T21:44:00+00:00\",\"dateModified\":\"2026-04-21T14:09:24+00:00\",\"description\":\"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you\",\"breadcrumb\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage\",\"url\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\",\"contentUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\",\"width\":1000,\"height\":1000,\"caption\":\"what is the difference between tirzepatide and semaglutide dosing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/getheally.com\/patients\/news\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatide vs semaglutide: key differences, efficacy &amp; which is right for you (2026)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#website\",\"url\":\"https:\/\/getheally.com\/patients\/news\/\",\"name\":\"Heally\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/getheally.com\/patients\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\",\"name\":\"Heally\",\"url\":\"https:\/\/getheally.com\/patients\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/wpcdn.getheally.com\/patients\/wp-content\/uploads\/2019\/05\/12231047\/heallybl.png\",\"contentUrl\":\"https:\/\/wpcdn.getheally.com\/patients\/wp-content\/uploads\/2019\/05\/12231047\/heallybl.png\",\"width\":152,\"height\":52,\"caption\":\"Heally\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/getheally.com\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/0c6491634669dd305779a764129e92d1\",\"name\":\"Vanessa Niles MD\",\"description\":\"Dr. Vanessa Niles is an Award-winning physician with more than 30 years of experience practicing medicine in the Obstetrics and Gynecology.\",\"sameAs\":[\"https:\/\/leafygreenagency.com\/about-dr-niles\/\",\"https:\/\/www.linkedin.com\/in\/drvanessaniles\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally","description":"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","og_locale":"en_US","og_type":"article","og_title":"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally","og_description":"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you","og_url":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","og_site_name":"Heally","article_publisher":"https:\/\/getheally.com","article_published_time":"2026-04-19T21:44:00+00:00","article_modified_time":"2026-04-21T14:09:24+00:00","og_image":[{"width":1000,"height":1000,"url":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","type":"image\/jpeg"}],"author":"Vanessa Niles MD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Vanessa Niles MD","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#article","isPartOf":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss"},"author":{"name":"Vanessa Niles MD","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/0c6491634669dd305779a764129e92d1"},"headline":"Tirzepatide vs semaglutide: key differences, efficacy &amp; which is right for you (2026)","datePublished":"2026-04-19T21:44:00+00:00","dateModified":"2026-04-21T14:09:24+00:00","mainEntityOfPage":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss"},"wordCount":2274,"publisher":{"@id":"https:\/\/getheally.com\/patients\/news\/#organization"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage"},"thumbnailUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","keywords":["Dosing","glp-1","Medication Comparison","mounjaro","Ozempic","semaglutide","tirzepatide","zepbound"],"articleSection":["Semaglutide","Tirzepatide"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","url":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","name":"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally","isPartOf":{"@id":"https:\/\/getheally.com\/patients\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage"},"thumbnailUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","datePublished":"2026-04-19T21:44:00+00:00","dateModified":"2026-04-21T14:09:24+00:00","description":"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you","breadcrumb":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage","url":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","contentUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","width":1000,"height":1000,"caption":"what is the difference between tirzepatide and semaglutide dosing"},{"@type":"BreadcrumbList","@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/getheally.com\/patients\/news"},{"@type":"ListItem","position":2,"name":"Tirzepatide vs semaglutide: key differences, efficacy &amp; which is right for you (2026)"}]},{"@type":"WebSite","@id":"https:\/\/getheally.com\/patients\/news\/#website","url":"https:\/\/getheally.com\/patients\/news\/","name":"Heally","description":"","publisher":{"@id":"https:\/\/getheally.com\/patients\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/getheally.com\/patients\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/getheally.com\/patients\/news\/#organization","name":"Heally","url":"https:\/\/getheally.com\/patients\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/","url":"https:\/\/wpcdn.getheally.com\/patients\/wp-content\/uploads\/2019\/05\/12231047\/heallybl.png","contentUrl":"https:\/\/wpcdn.getheally.com\/patients\/wp-content\/uploads\/2019\/05\/12231047\/heallybl.png","width":152,"height":52,"caption":"Heally"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/getheally.com"]},{"@type":"Person","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/0c6491634669dd305779a764129e92d1","name":"Vanessa Niles MD","description":"Dr. Vanessa Niles is an Award-winning physician with more than 30 years of experience practicing medicine in the Obstetrics and Gynecology.","sameAs":["https:\/\/leafygreenagency.com\/about-dr-niles\/","https:\/\/www.linkedin.com\/in\/drvanessaniles\/"]}]}},"_links":{"self":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/comments?post=29837"}],"version-history":[{"count":15,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29837\/revisions"}],"predecessor-version":[{"id":37263,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29837\/revisions\/37263"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/media\/29840"}],"wp:attachment":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/media?parent=29837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/categories?post=29837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/tags?post=29837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}